March 29, 2022, New York — Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has created a unique approach for identifying potential dual-purpose therapeutic targets for aging and age-associated diseases with PandaOmics, its proprietary AI-enabled biological target discovery platform. The research supporting this approach was published in Aging (March 2022).
Credit: Insilico
March 29, 2022, New York — Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has created a unique approach for identifying potential dual-purpose therapeutic targets for aging and age-associated diseases with PandaOmics, its proprietary AI-enabled biological target discovery platform. The research supporting this approach was published in Aging (March 2022).
People worldwide are living longer. According to the World Health Organization (WHO), one in six people in the world will be 60 years or older by 2030. However, aging increases vulnerability to a wide range of human disorders, including cancers, diabetes, cardiovascular diseases, and neurodegenerative diseases. Roughly two-thirds of the 150,000 people globally who die each day suffer from age-associated diseases.
Recent aging research suggests that targeting the aging process itself could ameliorate many age-related pathologies. The research proposed by Insilico Medicine’s scientists aims to utilize AI to identify potential targets that are implicated in multiple age-associated diseases and also play a role in the basic biology of aging. The results of this research may have substantial benefits for the discovery and development of therapeutics for both aging and age-associated diseases.
Insilico Medicine utilized its PandaOmics platform to perform target identification for 14 age-associated diseases (AADs) and 19 non-age-associated diseases (NAADs) across multiple disease areas to identify age-associated disease targets. As part of a comprehensive assessment, 145 genes were considered as potential aging-related targets and mapped into corresponding aging hallmark(s), including 69 high confidence targets with potential high druggability, 48 medium novel targets with potential medium to high druggability, and 28 highly novel targets with potential medium druggability.
“Developing interventions that target multiple age-associated diseases and aging itself could result in unprecedented health benefits by not only treating diseas, but also extending lifespan and providing for fresh drug repurposing candidates” said Alex Zhavoronkov PhD, CEO of Insilico Medicine. “The current study also demonstrated the power of the PandaOmics AI-powered target discovery platform to identify novel dual-purpose targets not only for specific disorders but across multiple types of diseases, enabling biologists and clinicians to further investigate their therapeutic potential in a cost-saving and time-efficient manner.”
A list of potential therapeutic dual-purpose aging targets for drug discovery was disclosed in the paper.
The paper is available here: https://www.aging-us.com/article/203960/text
About PandaOmics
PandaOmics enables systems biology research across multiple data types, including multi-omics and text data, and deploys AI-powered analytical capabilities to facilitate the rapid discovery of novel targets or the prioritization of established targets against diseases of interest. PandaOmics can serve as a business intelligence tool at the target identification stage of drug discovery in order to optimize portfolio development with strategies that can optimize for novelty and confidence.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.
For more information, visit www.insilico.com.
For media inquiry, please contact [email protected].
Journal
Aging-US
Article Title
Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine
